197 related articles for article (PubMed ID: 18443272)
1. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.
Montero JC; López-Pérez R; San Miguel JF; Pandiella A
Haematologica; 2008 Jun; 93(6):851-9. PubMed ID: 18443272
[TBL] [Abstract][Full Text] [Related]
2. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
3. Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.
Young SM; Cambareri AC; Odell A; Geary SM; Ashman LK
Cell Signal; 2007 Dec; 19(12):2572-81. PubMed ID: 17855052
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
5. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
[TBL] [Abstract][Full Text] [Related]
6. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
7. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts.
Caruana G; Cambareri AC; Ashman LK
Oncogene; 1999 Sep; 18(40):5573-81. PubMed ID: 10523834
[TBL] [Abstract][Full Text] [Related]
8. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
Yang M; Huang J; Pan HZ; Jin J
Int J Mol Med; 2008 Oct; 22(4):489-96. PubMed ID: 18813856
[TBL] [Abstract][Full Text] [Related]
9. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
[TBL] [Abstract][Full Text] [Related]
10. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.
Frost P; Shi Y; Hoang B; Lichtenstein A
Oncogene; 2007 Apr; 26(16):2255-62. PubMed ID: 17016437
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Maiso P; Carvajal-Vergara X; Ocio EM; López-Pérez R; Mateo G; Gutiérrez N; Atadja P; Pandiella A; San Miguel JF
Cancer Res; 2006 Jun; 66(11):5781-9. PubMed ID: 16740717
[TBL] [Abstract][Full Text] [Related]
13. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
Shaw TJ; Vanderhyden BC
Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
[TBL] [Abstract][Full Text] [Related]
14. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
[TBL] [Abstract][Full Text] [Related]
15. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.
Kobayashi T; Kuroda J; Ashihara E; Oomizu S; Terui Y; Taniyama A; Adachi S; Takagi T; Yamamoto M; Sasaki N; Horiike S; Hatake K; Yamauchi A; Hirashima M; Taniwaki M
Leukemia; 2010 Apr; 24(4):843-50. PubMed ID: 20200560
[TBL] [Abstract][Full Text] [Related]
16. Alkylating agents induce activation of NFkappaB in multiple myeloma cells.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Leuk Res; 2008 Jul; 32(7):1144-7. PubMed ID: 18083229
[TBL] [Abstract][Full Text] [Related]
17. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
Podar K; Shringarpure R; Tai YT; Simoncini M; Sattler M; Ishitsuka K; Richardson PG; Hideshima T; Chauhan D; Anderson KC
Cancer Res; 2004 Oct; 64(20):7500-6. PubMed ID: 15492276
[TBL] [Abstract][Full Text] [Related]
18. The prevalence and clinical implications of c-kit expression in plasma cell myeloma.
Pruneri G; Ponzoni M; Ferreri AJ; Freschi M; Tresoldi M; Baldini L; Mattioli M; Agnelli L; Govi S; Mancuso P; Agazzi A; Bertolini F; Peccatori J; Bosari S; Gianelli U; Viale G; Neri A
Histopathology; 2006 Apr; 48(5):529-35. PubMed ID: 16623778
[TBL] [Abstract][Full Text] [Related]
19. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
[TBL] [Abstract][Full Text] [Related]
20. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival.
Giuliani N; Bonomini S; Romagnani P; Lazzaretti M; Morandi F; Colla S; Tagliaferri S; Lasagni L; Annunziato F; Crugnola M; Rizzoli V
Haematologica; 2006 Nov; 91(11):1489-97. PubMed ID: 17082008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]